{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:41:21Z","timestamp":1768315281816,"version":"3.49.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T00:00:00Z","timestamp":1374710400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0069493","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T22:32:52Z","timestamp":1374791572000},"page":"e69493","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy"],"prefix":"10.1371","volume":"8","author":[{"given":"Ignacio","family":"P\u00e9rez-Valero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Gonz\u00e1lez-Baeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Est\u00e9banez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda L.","family":"Montes-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Bay\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 I.","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco X.","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Monge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Arnalich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 R.","family":"Arribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,7,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","article-title":"HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study","volume":"75","author":"RK Heaton","year":"2010","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0b013e3181a56de5","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis","volume":"51","author":"JR Arribas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","article-title":"The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/ml","volume":"24","author":"JR Arribas","year":"2010","journal-title":"AIDS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136","volume":"24","author":"C Katlama","year":"2010","journal-title":"AIDS"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e37442","DOI":"10.1371\/journal.pone.0037442","article-title":"Antiretroviral simplification with darunavir\/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile","volume":"7","author":"JR Santos","year":"2012","journal-title":"PLoS One"},{"key":"ref6","first-page":"179","article-title":"Curr HIV\/AIDS Rep","volume":"9","author":"M Est\u00e9banez","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society-USA Panel","volume":"308","author":"MA Thompson","year":"2012","journal-title":"JAMA"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2007.31","article-title":"Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System","volume":"65","author":"S Letendre","year":"2008","journal-title":"Arch Neurol"},{"key":"ref9","first-page":"1954","article-title":"Journal of Antimicrobial Chemotherapy","volume":"66","author":"I Perez-Valero","year":"2011","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"ref10","unstructured":"Santos J, Mu\u00f1oz-Moreno J, Molto J, Bravo I, Prats A, <etal>et al<\/etal>. (2012) Long-term Monotherapy with Lopinavir\/ritonavir (&gt;2 Years) Is Not Associated with Greater HIV-associated Neurocognitive Impairment. 19th Conference of Retroviruses and Opportunistic infections. Seattle, US. Abstract 483."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0b013e32833db9a1","article-title":"Randomized controlled study demonstrating failure of LPV\/r monotherapy in HIV: the role of compartment and CD4-nadir","volume":"24","author":"C Gutmann","year":"2010","journal-title":"AIDS"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAD.0b013e32835a9a4a","article-title":"Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV\/r-monotherapy","volume":"27","author":"RA Du Pasquier","year":"2013","journal-title":"AIDS"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"AS Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","article-title":"Updated research nosology for HIV-associated neurocognitive disorders","volume":"69","author":"A Antinori","year":"2007","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/13803390490510031","article-title":"Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection","volume":"26","author":"CL Carey","year":"2004","journal-title":"J Clin Exp Neuropsychol"},{"key":"ref16","unstructured":"Letendre SL, FitzSimons C, Ellis RJ, Clifford D, Collier AC, <etal>et al<\/etal>. (2010) Correlates of CSF Viral Loads in 1221 Volunteers of the CHARTER Cohort. 17th Conference of Retroviruses and Opportunistic infections. San Francisco, US. Abstract 172."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/QAD.0b013e3283354a7b","article-title":"Cognitive dysfunction in HIV patients despite long-standing suppression of viremia","volume":"24","author":"S Simioni","year":"2010","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/QAD.0b013e32834171f8","article-title":"Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort","volume":"25","author":"M Smurzynski","year":"2011","journal-title":"AIDS"},{"key":"ref19","unstructured":"Winston A, Arenas-Pinto A, St\u00f6hr W, Fisher M, Orkin c, <etal>et al<\/etal>. (2011) Factors influencing neurocognitive function in a large cohort of HIV infected patients on effective antiretroviral therapy. Thirteenth European AIDS Conference, Belgrade, Serbia. Abstract PS2\/4."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/WNL.54.4.927","article-title":"Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources","volume":"54","author":"RJ Ellis","year":"2000","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/01.aids.0000171409.38490.48","article-title":"Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV","volume":"19","author":"EV Capparelli","year":"2005","journal-title":"AIDS"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/aid.2008.0216","article-title":"Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals","volume":"25","author":"A Yilmaz","year":"2009","journal-title":"AIDS Research and Human Retroviruses"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1212\/WNL.0b013e3181dd4e31","article-title":"Therapeutic conundrum: AIDS therapies may be double-edged swords","volume":"74","author":"DB Clifford","year":"2010","journal-title":"Neurology"},{"key":"ref24","article-title":"Antiretroviral neurotoxicity","author":"K Robertson","year":"2012","journal-title":"J Neurovirol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1212\/WNL.0b013e3181d9ed09","article-title":"Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort","volume":"74","author":"KR Robertson","year":"2010","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/QAD.0b013e32832c4152","article-title":"Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance","volume":"23","author":"CM Marra","year":"2009","journal-title":"AIDS"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3109\/00365548.2012.690526","article-title":"Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir\/ritonavir monotherapy","volume":"44","author":"M Gisslen","year":"2012","journal-title":"Scand J Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/QAD.0b013e328342fb7b","article-title":"Inappropriate claim of \u201cfailure of ritonavir-boosted lopinavir monotherapy in HIV in the Monotherapy Switzerland\/Thailand (MOST) trial\u201d","volume":"25","author":"NI Paton","year":"2011","journal-title":"AIDS"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/650538","article-title":"Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy","volume":"50","author":"A Canestri","year":"2010","journal-title":"Clinical Infectious Diseases"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/QAD.0b013e328355e6b2","article-title":"Cerebrospinal Fluid HIV Escape Associated with Progressive Neurologic Dysfunction in Patients on Antiretroviral Therapy with Well-Controlled Plasma Viral Load","volume":"26","author":"MJ Peluso","year":"2012","journal-title":"AIDS"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1258\/ijsa.2011.011330","article-title":"Three-year evaluation of neuropsychiatric adverse events in the MONET trial of darunavir\/ritonavir, with or without nucleoside analogues","volume":"23","author":"A Winston","year":"2012","journal-title":"Int J STD AIDS"},{"key":"ref32","unstructured":"Panel members of the European AIDS Clinical Society (2012) European AIDS Clinical Society guidelines 2012. Version 6.1 Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.europeanaidsclinicalsociety.org\" xlink:type=\"simple\">www.europeanaidsclinicalsociety.org<\/ext-link>. Accessed: 14 April 2013."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0069493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T04:36:09Z","timestamp":1646195769000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0069493"}},"subtitle":[],"editor":[{"given":"Nicolas","family":"Sluis-Cremer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,25]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0069493","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,25]]}}}